Ceftriaxone for intramuscular injection is reconstituted by adding a specific volume of diluent (typically 1% lidocaine solution) into the powder vial, shaking thoroughly until dissolved, then withdrawing the full contents into a syringe. The exact volume of diluent depends on the vial size and your target concentration, either 250 mg/mL or 350 mg/mL.
Diluent Volumes by Vial Size
The FDA labeling provides two concentration options for IM reconstitution. The 250 mg/mL concentration uses more diluent and produces a larger injection volume. The 350 mg/mL concentration is more concentrated, meaning less fluid to inject, but it is not recommended for the 250 mg vial because the small total volume makes it difficult to withdraw the full dose.
- 250 mg vial: Add 0.9 mL of diluent (250 mg/mL concentration only)
- 500 mg vial: Add 1.8 mL for 250 mg/mL, or 1.0 mL for 350 mg/mL
- 1 g vial: Add 3.6 mL for 250 mg/mL, or 2.1 mL for 350 mg/mL
- 2 g vial: Add 7.2 mL for 250 mg/mL, or 4.2 mL for 350 mg/mL
The 350 mg/mL concentration is generally preferred for IM use because it keeps the injection volume smaller, which matters when you’re limited in how much fluid a single muscle site can handle.
Choosing the Right Diluent
For IM injection, 1% lidocaine hydrochloride solution (without epinephrine) is the diluent of choice. Ceftriaxone injected into muscle is painful, and using 1% lidocaine as the mixing liquid reduces pain by roughly 75% compared to sterile water. The manufacturer specifically recommends it for this reason.
Sterile water for injection can also be used but causes significantly more discomfort. Buffered lidocaine (made by adding sodium bicarbonate to 1% lidocaine) has been studied and shown to be bioequivalent, but it adds preparation steps with no meaningful pain advantage over plain 1% lidocaine. One critical safety note: lidocaine solution must never be injected intravenously, so this diluent is strictly for IM preparation.
Step-by-Step Reconstitution
Clean the rubber stopper of the ceftriaxone vial with an alcohol swab. Draw up the correct volume of 1% lidocaine into a syringe and inject it into the vial. Shake the vial thoroughly to dissolve the powder completely. The solution may appear light yellow to amber, which is normal and does not indicate degradation.
Once the powder is fully dissolved with no visible particles, withdraw the entire contents of the vial into the syringe. Change to a fresh needle before injection. For adults, a 22- to 25-gauge needle, 1 to 1.5 inches in length, is appropriate for deep IM administration. Select the longer needle for larger patients.
Injection Site and Volume Limits
Ceftriaxone should be injected deep into a large muscle. The ventrogluteal site (upper outer hip) is preferred. The dorsogluteal muscle is an alternative. No more than 1 g of ceftriaxone should be injected into a single site. If the prescribed dose is 2 g, split it between two separate injection sites, one on each side.
This volume limit is why the 350 mg/mL concentration is practical. A 1 g dose reconstituted at 350 mg/mL yields roughly 2.9 mL of solution per site, which is within the generally accepted range for a deep gluteal injection. At 250 mg/mL, that same dose would be about 4 mL, which is a large volume for a single site.
Calcium Interaction Warning
Ceftriaxone can form dangerous precipitates when mixed with calcium-containing IV solutions such as Ringer’s lactate or calcium-containing parenteral nutrition. This applies to IV administration and IV lines. However, the FDA labeling notes that no interaction has been reported between intramuscular ceftriaxone and calcium-containing products, whether IV or oral. Still, do not use any calcium-containing solution as a diluent for reconstitution.
Storage After Reconstitution
Ideally, ceftriaxone should be reconstituted immediately before use. If you need to prepare it in advance, reconstituted solutions remain stable at room temperature (25°C/77°F) for up to 24 hours and under refrigeration (2–8°C) for up to 10 days, depending on the diluent and concentration. Solutions prepared with lidocaine should be used promptly. Always inspect the solution before injection: it should be clear, free of particles, and range from pale yellow to amber in color. Discard any solution that appears cloudy or contains visible matter.